Rothschild Wealth LLC Has $1.47 Million Holdings in Merck & Co., Inc. $MRK

Rothschild Wealth LLC increased its holdings in Merck & Co., Inc. (NYSE:MRK) by 129.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,948 shares of the company’s stock after acquiring an additional 7,856 shares during the period. Rothschild Wealth LLC’s holdings in Merck & Co., Inc. were worth $1,468,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $25,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $26,000. IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $31,000. High Note Wealth LLC raised its holdings in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares during the last quarter. Finally, Gilpin Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $32,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. UBS Group upped their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. JPMorgan Chase & Co. upped their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. Finally, Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Stock Up 0.2%

Merck & Co., Inc. stock opened at $115.10 on Wednesday. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $125.14. The firm has a 50 day moving average price of $116.32 and a 200-day moving average price of $113.46. The company has a market capitalization of $284.27 billion, a P/E ratio of 32.42, a P/E/G ratio of 2.58 and a beta of 0.21. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. Merck & Co., Inc.’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period last year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 3.0%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.